See more : LESI GROUP (2540.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Pluri Inc. (PLUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pluri Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- CHW Acquisition Corporation (CHWA) Income Statement Analysis – Financial Results
- Dundee Corporation (DDEJF) Income Statement Analysis – Financial Results
- Ion Exchange (India) Limited (IONEXCHANG.NS) Income Statement Analysis – Financial Results
- Ceres Acquisition Corp. (CERWF) Income Statement Analysis – Financial Results
- Tritium DCFC Limited (DCFCQ) Income Statement Analysis – Financial Results
Pluri Inc. (PLUR)
About Pluri Inc.
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 326.00K | 287.00K | 234.00K | 0.00 | 23.00K | 54.00K | 50.00K | 0.00 | 2.85M | 379.00K | 379.00K | 679.00K | 716.00K | -1.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.00K | 9.00K | 41.59M | 50.62M | 1.57M | 2.00K | 2.00K | 2.18M | 100.00K | 13.00K | 11.00K | 20.00K | 21.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00K |
| Gross Profit | 322.00K | 278.00K | -41.36M | -50.62M | -1.55M | 52.00K | 48.00K | -2.18M | 2.75M | 366.00K | 368.00K | 659.00K | 695.00K | -1.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.00K |
| Gross Profit Ratio | 98.77% | 96.86% | -17,674.79% | 0.00% | -6,726.09% | 96.30% | 96.00% | 0.00% | 96.49% | 96.57% | 97.10% | 97.05% | 97.07% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.45M | 15.75M | 24.38M | 30.07M | 21.58M | 26.43M | 22.63M | 21.09M | 19.58M | 19.17M | 19.54M | 17.23M | 9.18M | 6.63M | 4.30M | 3.14M | 4.39M | 2.55M | 1.30M | 1.79M | 1.22M | 79.87K | 0.00 |
| General & Administrative | 10.03M | 11.78M | 17.45M | 20.56M | 7.92M | 9.16M | 11.19M | 6.93M | 6.49M | 6.46M | 8.68M | 5.65M | 6.57M | 4.49M | 3.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 112.96K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.66K | 0.00 |
| SG&A | 10.03M | 11.78M | 17.45M | 20.56M | 7.92M | 9.16M | 11.19M | 6.93M | 6.49M | 6.46M | 8.68M | 5.65M | 6.57M | 4.49M | 3.14M | 3.42M | 6.04M | 3.73M | 1.03M | 873.65K | 1.78M | 130.62K | 74.45K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -43.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 168.62K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.48M | 27.52M | 41.83M | 50.62M | 29.50M | 35.58M | 33.78M | 28.02M | 26.07M | 25.63M | 28.22M | 22.88M | 15.75M | 11.11M | 7.44M | 6.56M | 10.43M | 6.28M | 2.33M | 2.83M | 3.00M | 210.49K | 74.45K |
| Cost & Expenses | 22.48M | 27.53M | 41.83M | 50.62M | 29.50M | 35.59M | 33.78M | 28.02M | 26.17M | 25.65M | 28.23M | 22.90M | 15.75M | 11.11M | 7.44M | 6.56M | 10.43M | 6.28M | 2.33M | 2.83M | 3.00M | 210.49K | 74.45K |
| Interest Income | 1.31M | 1.08M | 581.00K | 492.00K | 384.00K | 385.00K | 276.00K | 122.00K | 149.00K | 112.00K | 246.00K | 266.00K | 575.00K | 236.00K | 2.00K | 14.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 866.00K | 843.00K | 887.00K | 78.00K | 196.00K | 29.00K | 937.00K | 0.00 | 100.00K | 37.00K | 36.00K | 29.00K | 12.00K | 13.00K | 31.00K | 8.00K | 0.00 | 23.02K | 0.00 | 0.00 | 0.00 | 0.00 | 3.45K |
| Depreciation & Amortization | 253.00K | 362.00K | 1.05M | 1.37M | 1.57M | 1.96M | 2.02M | 2.18M | 2.15M | 2.07M | 1.90M | 1.03M | 435.00K | 312.00K | 207.00K | 173.00K | 129.00K | 224.72K | 264.83K | 202.85K | 153.64K | 21.04K | 0.00 |
| EBITDA | -20.23M | -27.68M | -39.43M | -48.42M | -27.39M | -33.35M | -24.05M | -25.57M | -21.01M | -22.57M | -25.03M | -21.19M | -14.35M | -10.52M | -7.23M | -6.51M | -10.35M | -7.42M | -2.10M | -1.87M | -1.84M | 0.00 | -74.45K |
| EBITDA Ratio | -6,203.99% | -8,995.12% | -17,087.18% | 0.00% | -119,800.00% | -61,924.07% | -79,958.00% | 0.00% | -743.06% | -6,255.41% | -7,033.25% | -3,081.59% | -2,003.77% | 644.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.16M | -27.25M | -41.59M | -50.62M | -29.48M | -35.53M | -33.73M | -28.02M | -23.32M | -25.27M | -27.85M | -22.22M | -15.03M | -11.11M | -7.44M | -6.56M | -10.43M | -6.28M | -2.33M | -2.83M | -3.00M | -456.96K | -74.45K |
| Operating Income Ratio | -6,796.93% | -9,493.38% | -17,774.79% | 0.00% | -128,156.52% | -65,800.00% | -67,462.00% | 0.00% | -819.07% | -6,666.75% | -7,348.28% | -3,272.90% | -2,099.30% | 660.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 814.00K | -1.64M | 219.00K | 758.00K | 324.00K | 225.00K | 7.61M | 205.00K | 73.00K | 590.00K | 918.00K | 1.07M | 237.00K | 266.00K | -14.00K | -84.00K | -69.00K | -2.15M | -107.46K | 731.65K | 994.18K | 0.00 | 0.00 |
| Income Before Tax | -21.34M | -28.89M | -41.37M | -49.87M | -29.15M | -35.31M | -26.13M | -27.81M | -23.25M | -24.68M | -26.93M | -21.16M | -14.79M | -11.07M | -7.46M | -6.64M | 0.00 | -8.24M | 0.00 | -2.09M | 0.00 | 418.26K | 0.00 |
| Income Before Tax Ratio | -6,547.24% | -10,065.16% | -17,681.20% | 0.00% | -126,747.83% | -65,383.33% | -52,252.00% | 0.00% | -816.51% | -6,511.08% | -7,106.07% | -3,115.61% | -2,066.20% | 658.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 277.00K | -351.00K | 78.00K | 196.00K | -94.00K | 7.61M | -205.00K | -73.00K | -590.00K | -918.00K | 29.00K | 249.00K | -266.00K | 14.00K | 78.00K | 69.00K | 2.15M | 107.46K | -731.65K | -994.17K | 252.51K | 77.90K |
| Net Income | -20.89M | -28.32M | -41.02M | -49.94M | -29.35M | -35.21M | -26.13M | -27.81M | -23.25M | -24.68M | -26.93M | -21.16M | -14.79M | -10.85M | -7.45M | -6.64M | -10.50M | -8.43M | -2.44M | -2.10M | -2.01M | -463.00K | -77.90K |
| Net Income Ratio | -6,407.36% | -9,867.94% | -17,531.20% | 0.00% | -127,600.00% | -65,209.26% | -52,252.00% | 0.00% | -816.51% | -6,511.08% | -7,106.07% | -3,115.61% | -2,066.20% | 644.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.99 | -6.18 | -10.19 | -14.21 | -12.90 | -22.84 | -19.74 | -25.45 | -23.38 | -28.09 | -33.92 | -30.50 | -26.88 | -27.82 | -35.06 | -50.07 | -130.77 | -467.52 | -639.99 | -822.71 | -120.34 | -27.71 | -4.66 |
| EPS Diluted | -3.99 | -6.18 | -10.19 | -14.21 | -12.90 | -22.84 | -19.74 | -25.45 | -23.38 | -28.09 | -33.92 | -30.50 | -26.88 | -27.82 | -35.06 | -50.07 | -130.77 | -467.52 | -639.99 | -822.71 | -120.34 | -27.71 | -4.66 |
| Weighted Avg Shares Out | 5.24M | 4.58M | 4.02M | 3.51M | 2.27M | 1.54M | 1.32M | 1.09M | 994.35K | 878.55K | 793.93K | 693.52K | 550.40K | 389.99K | 212.56K | 132.54K | 80.28K | 18.03K | 3.81K | 2.55K | 16.71K | 16.71K | 16.71K |
| Weighted Avg Shares Out (Dil) | 5.24M | 4.58M | 4.02M | 3.51M | 2.27M | 1.54M | 1.32M | 1.09M | 994.35K | 878.55K | 793.93K | 693.52K | 550.40K | 389.99K | 212.56K | 132.54K | 80.28K | 18.03K | 3.81K | 2.55K | 16.71K | 16.71K | 16.71K |
Pluri Inc. Announces 1-for-8 Reverse Share Split
HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), a leading biotechnology company that transforms cells into solutions, today announced that a reverse share split of the Company's issued and outstanding...
Pluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report
HAIFA, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today addressed the price volatility challenge detailed in the...
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
HAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today announced its participation in the following upcoming conferences.
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
PluriCDMO™ will support Remedy Cell in the manufacture of RC-0315 product candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF) PluriCDMO™ will support Remedy Cell in the manufacture of RC-0315 product candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF)
Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
Patent helps position Pluri as a leader in cell expansion for the agtech industry with the launch of its PluriAgtech business vertical and cell-based coffee product Patent helps position Pluri as a leader in cell expansion for the agtech industry...
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James...
Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals
HAIFA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) (“Pluri” or the “Company”) today issued the following update from CEO and President, Yaky Yanay:
Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis
HAIFA, Israel, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global well-being and sustainability, announced today that it has launched its...
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
Pluri, an established global leader in the development and manufacturing of cell-based therapeutics, launches new revenue-generating Contract Development and Manufacturing Organization (CDMO) division. PluriCDMO ™ will help innovative companies develop and manufacture life-changing therapies within the rapidly growing $5.2 billion...
Pluri's PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation
HAIFA, Israel, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the publication of an article titled...
Source: https://incomestatements.info
Category: Stock Reports